OTCMKTS:PMCUF Pro Medicus (PMCUF) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free PMCUF Stock Alerts $66.18 0.00 (0.00%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$66.18▼$66.1850-Day Range$58.67▼$73.0452-Week Range$38.19▼$73.04VolumeN/AAverage Volume514 shsMarket CapitalizationN/AP/E Ratio4,412.00Dividend Yield0.03%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Pro Medicus alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Pro Medicus Stock (OTCMKTS:PMCUF)Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.Read More PMCUF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PMCUF Stock News HeadlinesMarch 6, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pro Medicus Limited (OtherPMCUF) and Ramsay Health Care (OtherRMSYF)February 15, 2024 | wsj.comPro Medicus Ltd.April 18, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…February 15, 2024 | msn.comPro Medicus reports 1H resultsFebruary 14, 2024 | msn.comIs this as good as it gets for Pro Medicus?February 2, 2024 | finance.yahoo.comVisage Launches Visage Ease VP™ for Apple Vision ProJanuary 4, 2024 | markets.businessinsider.comJefferies Reaffirms Their Hold Rating on Pro Medicus Limited (PMCUF)December 16, 2023 | morningstar.comPro Medicus Ltd PMCUFApril 18, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…December 15, 2023 | seekingalpha.comPMCUF Pro Medicus LimitedDecember 14, 2023 | afr.comHow Sam Hupert turned Pro Medicus into an understated giantDecember 12, 2023 | finance.yahoo.comPro Medicus Limited's (ASX:PME) Stock Is Going Strong: Is the Market Following Fundamentals?November 26, 2023 | au.investing.comPro Medicus (ASX: PME): A Phenomenal Surge of 784% in ASX 200 Healthcare in last 5 yearsNovember 20, 2023 | afr.comPro Medicus founders in $176m selldown; Unified Capital nabs tradeNovember 4, 2023 | morningstar.comPro Medicus Ltd PMEOctober 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Allakos (ALLK), Pro Medicus Limited (OtherPMCUF) and Exelixis (EXEL)October 8, 2023 | finance.yahoo.comPro Medicus (ASX:PME) Could Become A Multi-BaggerOctober 7, 2023 | morningstar.com.auIs the stock price surge of Pro Medicus justifiedSeptember 27, 2023 | markets.businessinsider.comPro Medicus Limited (PMCUF) Gets a Buy from WilsonsSeptember 26, 2023 | markets.businessinsider.comPro Medicus Limited (PMCUF) Gets a Hold from CitiSeptember 26, 2023 | markets.businessinsider.comGoldman Sachs Remains a Buy on Pro Medicus Limited (PMCUF)August 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Cochlear Limited (OtherCHEOF) and Pro Medicus Limited (OtherPMCUF)August 16, 2023 | markets.businessinsider.comMoelis Reaffirms Their Hold Rating on Pro Medicus Limited (PMCUF)August 15, 2023 | markets.businessinsider.comPro Medicus Limited (PMCUF) was upgraded to a Hold Rating at MorgansAugust 15, 2023 | finance.yahoo.comPro Medicus Full Year 2023 Earnings: Beats ExpectationsAugust 15, 2023 | fool.com.auPro Medicus share price jumps on 36% profit growth in FY23 reportAugust 15, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Their Buy Rating for Pro Medicus Limited (PMCUF)See More Headlines Receive PMCUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro Medicus and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolOTCMKTS:PMCUF CUSIPN/A CIKN/A Webwww.promed.com.au Phone61 3 9429 8800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio4,412.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Sam Aaron Hupert M.B.B.S.M.D., Co-Founder, CEO, MD & Executive DirectorMr. Anthony Barry Hall B.Sc.B.Sc.(Hons), M.Sc., Co-Founder, Technology Director & Executive DirectorMr. Clayton James Hatch B.CommCPA, CPA, Chief Financial OfficerDr. Malte WesterhoffGM of Europe & Global CTOMr. Brad LevinGM of North America & Global Head of MarketingMs. Sharni L. RedenbachPeople & Culture DirectorMr. Sean LambrightGlobal Head of Sales - Visage Imaging IncMs. Teresa GschwindGlobal Head of Customer Service of Visage Imaging Inc.Ms. Danny English C.A.Financial Controller & Company SecretaryMore ExecutivesKey CompetitorsAclarionNASDAQ:ACONWArcturis DataOTCMKTS:SSYNFAscomOTCMKTS:ACMLFBinovi TechnologiesOTCMKTS:BNVIFBrightSpring Health ServicesNASDAQ:BTSGUView All Competitors PMCUF Stock Analysis - Frequently Asked Questions Should I buy or sell Pro Medicus stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pro Medicus in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PMCUF shares. View PMCUF analyst ratings or view top-rated stocks. How have PMCUF shares performed in 2024? Pro Medicus' stock was trading at $64.75 at the beginning of the year. Since then, PMCUF stock has increased by 2.2% and is now trading at $66.18. View the best growth stocks for 2024 here. Is Pro Medicus a good dividend stock? Pro Medicus (OTCMKTS:PMCUF) pays an annual dividend of $0.02 per share and currently has a dividend yield of 1.63%. The dividend payout ratio is 133.33%. Payout ratios above 75% are not desirable because they may not be sustainable. How do I buy shares of Pro Medicus? Shares of PMCUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PMCUF) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIBiden replacement revealed?Paradigm PressThe “Perfect Storm” for GoldGold Safe ExchangeThe #1 Crypto for 2024InvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pro Medicus Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.